Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease

Omar M.A. El-Agnaf, Sultan A. Salem, Katerina E. Paleologou, Martin D. Curran, Mark J. Gibson, Jennifer A. Court, Michael G. Schlossmacher, David Allsop

Research output: Contribution to journalArticle

442 Citations (Scopus)

Abstract

To date there is no accepted clinical diagnostic test for Parkinson's disease (PD) based on biochemical analysis of blood or cerebrospinal fluid (CSF). α-Synuclein (α-syn) protein has been linked to the pathogenesis of PD with the discovery of mutations in the gene encoding α-syn in familial cases with early-onset PD. Lewy bodies and Lewy neurites, which constitute the main pathological features in the brains of patients with sporadic PD and dementia with Lewy bodies, are formed by the conversion of soluble monomers of α-syn into insoluble aggregates. We recently reported the presence of α-syn in normal human blood plasma and in postmortem CSF. Here, we investigated whether α-syn can be used as a biomarker for PD. We have developed a novel ELISA method that detects only oligomeric "soluble aggregates" of α-syn. Using this ELISA, we report the presence of significantly elevated (P=0.002) levels of oligomeric forms of α-syn in plasma samples obtained from 34 PD patients compared with 27 controls; 52% (95% confidence intervals 0.353-0.687) of the PD patients displayed signals >0.5 OD with our ELISA assay in comparison to only 14.8% (95% confidence intervals 0.014-0.281) for the control cases. An analysis of the test's diagnostic value revealed a specificity of 0.852 (95% confidence intervals 0.662-0.958), sensitivity of 0.529 (95% confidence intervals 0.351-0.702) and a positive predictive value of 0.818 (95% confidence intervals 0.597-0.948). These observations offer new opportunities for developing diagnostic tests for PD and related diseases and for testing therapeutic agents aimed at preventing or reversing the aggregation of α-syn.

Original languageEnglish
Pages (from-to)419-425
Number of pages7
JournalFASEB Journal
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 2006
Externally publishedYes

Fingerprint

Synucleins
Plasma (human)
Biomarkers
Parkinson Disease
Confidence Intervals
Proteins
Routine Diagnostic Tests
Cerebrospinal fluid
Enzyme-Linked Immunosorbent Assay
Cerebrospinal Fluid
Blood
Lewy Bodies
Lewy Body Disease
Plasmas
Gene encoding
Neurites
Assays
Brain
Agglomeration
Monomers

Keywords

  • α-syn fibrils
  • CSF
  • Lewy bodies
  • Oligomers
  • PD

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. / El-Agnaf, Omar M.A.; Salem, Sultan A.; Paleologou, Katerina E.; Curran, Martin D.; Gibson, Mark J.; Court, Jennifer A.; Schlossmacher, Michael G.; Allsop, David.

In: FASEB Journal, Vol. 20, No. 3, 03.2006, p. 419-425.

Research output: Contribution to journalArticle

El-Agnaf, OMA, Salem, SA, Paleologou, KE, Curran, MD, Gibson, MJ, Court, JA, Schlossmacher, MG & Allsop, D 2006, 'Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease', FASEB Journal, vol. 20, no. 3, pp. 419-425. https://doi.org/10.1096/fj.03-1449com
El-Agnaf, Omar M.A. ; Salem, Sultan A. ; Paleologou, Katerina E. ; Curran, Martin D. ; Gibson, Mark J. ; Court, Jennifer A. ; Schlossmacher, Michael G. ; Allsop, David. / Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. In: FASEB Journal. 2006 ; Vol. 20, No. 3. pp. 419-425.
@article{417af773206f492daabbb8a163a0e502,
title = "Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease",
abstract = "To date there is no accepted clinical diagnostic test for Parkinson's disease (PD) based on biochemical analysis of blood or cerebrospinal fluid (CSF). α-Synuclein (α-syn) protein has been linked to the pathogenesis of PD with the discovery of mutations in the gene encoding α-syn in familial cases with early-onset PD. Lewy bodies and Lewy neurites, which constitute the main pathological features in the brains of patients with sporadic PD and dementia with Lewy bodies, are formed by the conversion of soluble monomers of α-syn into insoluble aggregates. We recently reported the presence of α-syn in normal human blood plasma and in postmortem CSF. Here, we investigated whether α-syn can be used as a biomarker for PD. We have developed a novel ELISA method that detects only oligomeric {"}soluble aggregates{"} of α-syn. Using this ELISA, we report the presence of significantly elevated (P=0.002) levels of oligomeric forms of α-syn in plasma samples obtained from 34 PD patients compared with 27 controls; 52{\%} (95{\%} confidence intervals 0.353-0.687) of the PD patients displayed signals >0.5 OD with our ELISA assay in comparison to only 14.8{\%} (95{\%} confidence intervals 0.014-0.281) for the control cases. An analysis of the test's diagnostic value revealed a specificity of 0.852 (95{\%} confidence intervals 0.662-0.958), sensitivity of 0.529 (95{\%} confidence intervals 0.351-0.702) and a positive predictive value of 0.818 (95{\%} confidence intervals 0.597-0.948). These observations offer new opportunities for developing diagnostic tests for PD and related diseases and for testing therapeutic agents aimed at preventing or reversing the aggregation of α-syn.",
keywords = "α-syn fibrils, CSF, Lewy bodies, Oligomers, PD",
author = "El-Agnaf, {Omar M.A.} and Salem, {Sultan A.} and Paleologou, {Katerina E.} and Curran, {Martin D.} and Gibson, {Mark J.} and Court, {Jennifer A.} and Schlossmacher, {Michael G.} and David Allsop",
year = "2006",
month = "3",
doi = "10.1096/fj.03-1449com",
language = "English",
volume = "20",
pages = "419--425",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease

AU - El-Agnaf, Omar M.A.

AU - Salem, Sultan A.

AU - Paleologou, Katerina E.

AU - Curran, Martin D.

AU - Gibson, Mark J.

AU - Court, Jennifer A.

AU - Schlossmacher, Michael G.

AU - Allsop, David

PY - 2006/3

Y1 - 2006/3

N2 - To date there is no accepted clinical diagnostic test for Parkinson's disease (PD) based on biochemical analysis of blood or cerebrospinal fluid (CSF). α-Synuclein (α-syn) protein has been linked to the pathogenesis of PD with the discovery of mutations in the gene encoding α-syn in familial cases with early-onset PD. Lewy bodies and Lewy neurites, which constitute the main pathological features in the brains of patients with sporadic PD and dementia with Lewy bodies, are formed by the conversion of soluble monomers of α-syn into insoluble aggregates. We recently reported the presence of α-syn in normal human blood plasma and in postmortem CSF. Here, we investigated whether α-syn can be used as a biomarker for PD. We have developed a novel ELISA method that detects only oligomeric "soluble aggregates" of α-syn. Using this ELISA, we report the presence of significantly elevated (P=0.002) levels of oligomeric forms of α-syn in plasma samples obtained from 34 PD patients compared with 27 controls; 52% (95% confidence intervals 0.353-0.687) of the PD patients displayed signals >0.5 OD with our ELISA assay in comparison to only 14.8% (95% confidence intervals 0.014-0.281) for the control cases. An analysis of the test's diagnostic value revealed a specificity of 0.852 (95% confidence intervals 0.662-0.958), sensitivity of 0.529 (95% confidence intervals 0.351-0.702) and a positive predictive value of 0.818 (95% confidence intervals 0.597-0.948). These observations offer new opportunities for developing diagnostic tests for PD and related diseases and for testing therapeutic agents aimed at preventing or reversing the aggregation of α-syn.

AB - To date there is no accepted clinical diagnostic test for Parkinson's disease (PD) based on biochemical analysis of blood or cerebrospinal fluid (CSF). α-Synuclein (α-syn) protein has been linked to the pathogenesis of PD with the discovery of mutations in the gene encoding α-syn in familial cases with early-onset PD. Lewy bodies and Lewy neurites, which constitute the main pathological features in the brains of patients with sporadic PD and dementia with Lewy bodies, are formed by the conversion of soluble monomers of α-syn into insoluble aggregates. We recently reported the presence of α-syn in normal human blood plasma and in postmortem CSF. Here, we investigated whether α-syn can be used as a biomarker for PD. We have developed a novel ELISA method that detects only oligomeric "soluble aggregates" of α-syn. Using this ELISA, we report the presence of significantly elevated (P=0.002) levels of oligomeric forms of α-syn in plasma samples obtained from 34 PD patients compared with 27 controls; 52% (95% confidence intervals 0.353-0.687) of the PD patients displayed signals >0.5 OD with our ELISA assay in comparison to only 14.8% (95% confidence intervals 0.014-0.281) for the control cases. An analysis of the test's diagnostic value revealed a specificity of 0.852 (95% confidence intervals 0.662-0.958), sensitivity of 0.529 (95% confidence intervals 0.351-0.702) and a positive predictive value of 0.818 (95% confidence intervals 0.597-0.948). These observations offer new opportunities for developing diagnostic tests for PD and related diseases and for testing therapeutic agents aimed at preventing or reversing the aggregation of α-syn.

KW - α-syn fibrils

KW - CSF

KW - Lewy bodies

KW - Oligomers

KW - PD

UR - http://www.scopus.com/inward/record.url?scp=33645833848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645833848&partnerID=8YFLogxK

U2 - 10.1096/fj.03-1449com

DO - 10.1096/fj.03-1449com

M3 - Article

C2 - 16507759

AN - SCOPUS:33645833848

VL - 20

SP - 419

EP - 425

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -